WallStSmart

Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6280% more annual revenue ($66.57B vs $1.04B). MRK leads profitability with a 4.8% profit margin vs -2.7%. LMRI earns a higher WallStSmart Score of 35/100 (F).

LMRI

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 7/9Altman Z: 0.57

MRK

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LMRI.

MRKSignificantly Overvalued (-84.6%)

Margin of Safety

-84.6%

Fair Value

$82.62

Current Price

$149.54

$66.92 premium

UndervaluedFair: $82.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LMRI2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$335.46B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

LMRI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.19B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.2%3/10

Operating margin of 3.2%

Return on EquityProfitability
-10.0%2/10

ROE of -10.0% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LMRI

The strongest argument for LMRI centers on Debt/Equity, Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : LMRI

The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

LMRI profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LMRI scores higher overall (35/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lumexa Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?